Digirad Corporation (NASDAQ:DRAD) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: September 23, 2016
Zacks Investment Research has downgraded Digirad Corporation (NASDAQ:DRAD) to Sell in a statement released on 9/23/2016.
Boasting a price of $4.99, Digirad Corporation (NASDAQ:DRAD) traded 1.63% higher on the day. With the last stock price close down -5.03% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Digirad Corporation has recorded a 50-day average of $5.07 and a two hundred day average of $5.25. Volume of trade was down over the average, with 31,613 shares of DRAD changing hands under the typical 57,950
With a total market value of $0, Digirad Corporation has price-earnings ratio of 3.06 with a one year low of $3.65 and a 52 week high of $6.92 .
About Digirad Corporation (NASDAQ:DRAD)
Digirad Corporation is a provider of diagnostic solutions. The Company's business is organized into two segments: Diagnostic Services and Diagnostic Imaging. The Company provides in-office nuclear cardiology and ultrasound imaging services. It also provides cardiac event monitoring services to physician practices, hospitals and imaging centers through its Diagnostic Services business segment. The Company sells solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products it sells through its Diagnostic Imaging business segment. Diagnostic Services also offers remote cardiac event monitoring services, which include provision of a monitor, remote monitoring by registered nurses and monitoring support for its patients and physician customers. Its nuclear cameras feature detectors based on solid-state technology. Its cameras are used in hospitals, imaging centers, physician offices, and by mobile service providers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.